Nov 16, 2020Seqirus Will Build World-class, Next-generation $800m Influenza Vaccine Manufacturing Facility in Australia
16 Nov 2020 Seqirus will build the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere – producing seasonal and pandemic flu vaccines, Seqirus’ proprietary...
Oct 29, 2020
Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year 29 Oct 2020 Forbes magazine has named global biotechnology leader CSL Limited to its World’s Best Employers 2020 list. It...
Oct 14, 2020This EU Flu Day, Seqirus confirms record number of influenza vaccines delivered across Europe to meet increased demand
The first annual EU Flu Day was launched today, 14 October 2020. Marking the occasion, Seqirus, a global leader in influenza prevention, announced that it has delivered shipments of influenza...
Sep 7, 2020CSL to manufacture and supply University of Queensland and Oxford University vaccine candidates for Australia
CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19...
Jul 30, 2020
Summit, NJ 30 Jul 2020 Seqirus has started shipping its portfolio of seasonal influenza vaccines to United States (U.S.) customers for the upcoming 2020/21 U.S. influenza season Seqirus is...